Savient Pharmaceuticals

Latest Headlines

Latest Headlines

Savient hammered after hedge fund claims it's bankrupt

John Johnson has a good reason today to be thankful for his new job at Dendreon: He won't have to face the music at Savient.

Gold out, Johnson in as troubled Dendreon aims for a turnaround

In the course of one short year, Dendreon CEO Mitch Gold went from biotech hero to zero as the long-anticipated rollout of the groundbreaking cancer vaccine Provenge stumbled badly out of the gate....

Savient shares plunge after takeover talk fizzles

Woe is Savient Pharmaceuticals. The company finally succeeded in getting its gout drug Krystexxa approved by FDA--its first and only product so far--but lacks the money for a major launch. And its

Savient wins FDA approval of gout drug Krystexxa

Savient Pharmaceuticals has won FDA approval for Kyrstexxa (pegloticase), a closely-watched drug for chronic gout in adult patients refractory to conventional therapy. Gout, which affects more than 5

Four drugs look to pass FDA muster this month

Brian Orelli of The Motley Fool highlights four drugs--AstraZeneca's Brilinta, Questcor's Acthar Gel, Savient's Krystexxa and Novartis' Gilenia--that could gain FDA approval this month despite some

Savient shares rise on Amgen takeover talk

Shares of Savient Pharmaceuticals (SVNT) were up as much as 5 percent today on rumors that Amgen is interested in acquiring the company. Savient has submitted a BLA for its closely-watched gout drug

Savient Pharma to cut 38% of staff

Savient Pharmaceuticals (SVNT) today announced plans to reduce costs by slashing its headcount by 38 percent--or 26 jobs--as it prepares to resubmit its BLA for investigational gout drug Krystexxa.

Savient says gout drug on track, no trial needed

Savient Pharmaceuticals says it's on track to resubmit its closely-watched gout drug for FDA marketing approval by the early part of 2010 after the FDA made it clear in a recent meeting that the

Savient's gout drug gets FDA response letter

Savient Pharmaceuticals announced on Sunday that the FDA issued a complete response letter for the drugmaker's gout drug Krystexxa (pegloticase), causing the company's shares to fall 38 percent in

Savient shares skyrocket on FDA's Krystexxa remarks

Shares of Savient Pharmaceuticals barreled ahead more than 50 percent this morning after analysts had a chance to digest FDA staff remarks on the gout drug Krystexxa, which is up for a panel review